### Analysis of rs121913529 Variant and Its Impact on Gene Structure and Function

#### 1. **Variant Identification**
   - **rs Number**: [rs121913529](https://identifiers.org/dbsnp/rs121913529)
   - **Gene**: KRAS (Kirsten rat sarcoma viral oncogene homolog)
   - **Chromosome**: 12
   - **Position**: 25245350 (GRCh38)
   - **HGVS Notations**:
     - **cDNA**: Multiple transcripts, e.g., `NM_004985.5:c.35G>T`, `NM_004985.5:c.35G>C`, `NM_004985.5:c.35G>A`
     - **Protein**: Corresponding changes include `p.Gly12Val`, `p.Gly12Ala`, and `p.Gly12Asp`
   - **TogoVar Link**: [TogoVar rs121913529](https://togovar.org/variant/rs121913529)

#### 2. **Impact on Gene Function**
   - The rs121913529 variant is located in the **KRAS gene**, which encodes a small GTPase involved in cell signaling pathways that regulate cell growth, differentiation, and survival.
   - The variant results in **missense mutations** at codon 12 of the KRAS protein, substituting glycine (Gly) with valine (Val), alanine (Ala), or aspartic acid (Asp). These changes occur in the GTP-binding domain, a critical region for KRAS function.
   - **Functional Consequences**:
     - **Gain-of-function mutations**: These substitutions lead to constitutive activation of KRAS, rendering it continuously active in its GTP-bound state. This disrupts normal signaling and promotes uncontrolled cell proliferation, a hallmark of cancer.
     - **Structural Impact**: The substitutions alter the protein's conformation, particularly in the GTP-binding pocket, reducing its ability to hydrolyze GTP to GDP. This locks KRAS in an active state.

#### 3. **Disease Associations**
   - The rs121913529 variant is strongly associated with various cancers, including:
     - **Non-small cell lung carcinoma (NSCLC)**
     - **Colorectal cancer**
     - **Pancreatic cancer**
     - **Acute myeloid leukemia (AML)**
   - These associations are supported by clinical databases such as ClinVar and MGEND, with pathogenic interpretations.

#### 4. **Predictive Models**
   - **AlphaMissense**: High pathogenicity score (0.9949–0.9984), indicating a strong likelihood of functional disruption.
   - **SIFT**: Scores range from 0.0 to 0.14, suggesting the variant is "deleterious."
   - **PolyPhen-2**: Scores range from 0.041 to 0.985, indicating the variant is "probably damaging."

#### 5. **Allele Frequency**
   - The variant is rare in the general population:
     - **gnomAD Exomes**: Allele frequency of 6.8e-07 to 2.7e-06
     - **gnomAD Genomes**: Allele frequency of 1.3e-05
   - No significant population-specific differences were noted.

#### 6. **GWAS Findings**
   - No direct GWAS findings were retrieved for this variant. However, its role in cancer pathways is well-documented in functional studies.

#### 7. **Literature Evidence**
   - The rs121913529 variant has been extensively studied in the context of cancer biology. It is a well-known driver mutation in oncogenesis, particularly in KRAS-driven cancers.

---

### Summary in Japanese (日本語での要約)

#### 1. **変異の特定**
   - **rs番号**: [rs121913529](https://identifiers.org/dbsnp/rs121913529)
   - **遺伝子**: KRAS
   - **染色体**: 12
   - **位置**: 25245350 (GRCh38)
   - **HGVS表記**:
     - **cDNA**: 例: `NM_004985.5:c.35G>T`, `NM_004985.5:c.35G>C`, `NM_004985.5:c.35G>A`
     - **タンパク質**: `p.Gly12Val`, `p.Gly12Ala`, `p.Gly12Asp`
   - **TogoVarリンク**: [TogoVar rs121913529](https://togovar.org/variant/rs121913529)

#### 2. **遺伝子機能への影響**
   - **KRAS遺伝子**は細胞増殖や分化を制御するシグナル伝達経路に関与。
   - この変異はKRASタンパク質の12番目のコドンにミスセンス変異を引き起こし、グリシン（Gly）がバリン（Val）、アラニン（Ala）、またはアスパラギン酸（Asp）に置換される。
   - **機能的影響**:
     - **機能獲得型変異**: KRASが恒常的に活性化され、制御不能な細胞増殖を引き起こす。
     - **構造的影響**: GTP結合ポケットの構造が変化し、GTPの加水分解が阻害される。

#### 3. **疾患との関連**
   - この変異は以下のがんと強く関連:
     - **非小細胞肺がん (NSCLC)**
     - **大腸がん**
     - **膵臓がん**
     - **急性骨髄性白血病 (AML)**

#### 4. **予測モデル**
   - **AlphaMissense**: 高い病原性スコア (0.9949–0.9984)
   - **SIFT**: 「有害」と予測 (スコア: 0.0–0.14)
   - **PolyPhen-2**: 「おそらく有害」(スコア: 0.041–0.985)

#### 5. **アレル頻度**
   - 一般集団では稀:
     - **gnomAD Exomes**: アレル頻度 6.8e-07～2.7e-06
     - **gnomAD Genomes**: アレル頻度 1.3e-05

#### 6. **GWASの発見**
   - この変異に直接関連するGWASの結果は見つかりませんでしたが、がんにおける役割は広く研究されています。

#### 7. **文献的証拠**
   - rs121913529はがん生物学において広く研究されており、KRAS駆動型がんの主要なドライバー変異として知られています。

---

### References
- [TogoVar rs121913529](https://togovar.org/variant/rs121913529)
- [gnomAD Variant Browser](https://gnomad.broadinstitute.org/variant/12-25245350-C-T?dataset=gnomad_r4)